We have previously reported that inhibition of thromboxane synthesis results in an improvement in postischemic function in stunned myocardium of dogs. The purpose of the present study was to investigate further the mechanism by which thromboxane synthesis inhibition improves recovery of function in stunned myocardium (15 minutes of coronary occlusion and 3 hours of reperfusion) in barbital anesthetized dogs. The recovery of regional myocardial wall function (percent segment shortening, % SS) following treatment with two doses (0.5 and 10 mg/kg) of a thromboxane receptor blocker, BM 13.505, given prior to coronary occlusion, was not different from that of a control group (3-hour % SS of pretreatment control, PTC, 12 +11) throughout reperfusion (3-hour % SS of PTC with BM 13.505: 0.5 mg/kg 14±+10; 10 mg/kg, 27±9). In contrast, the specific thromboxane synthetase inhibitor, dazmegrel (3.0 mg/kg), significantly improved % SS throughout reperfusion (3-hour % SS of PTC, 66+ 8). In addition, while dazmegrel produced a marked decrease in thromboxane, 6-keto-PGF,. was significantly increased in coronary venous blood throughout the occlusion and reperfusion period. The cyclooxygenase inhibitor, indomethacin, had no beneficial effect on functional recovery (3-hour % SS of PTC, 5 6), attenuated the dazmegrel induced shunting to prostacyclin, and completely prevented the beneficial effects of dazmegrel on functional recovery (3-hour % SS of PTC, 17+12). Thus, a redirection to endogenous cardioprotective prostanoids, such as prostacyclin, appears to be responsible for the beneficial effect of thromboxane synthesis inhibition on postischemic recovery in stunned myocardium whereas thromboxane does not appear to be an important mediator of the stunning phenomenon. (Circulation 1990;81:369-380) F ollowing brief periods of myocardial ischemia (less than 20 minutes in dogs), no myocyte necrosis results, but there are prolonged, reversible abnormalities in myocardial contractile function, descriptively known as the stunned myocardium.1 Although the myocardium eventually recovers from these transient ischemic episodes, the underlying mechanism(s) responsible for and mediators involved in the reversible dysfunction remain unknown.
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F ollowing brief periods of myocardial ischemia (less than 20 minutes in dogs), no myocyte necrosis results, but there are prolonged, reversible abnormalities in myocardial contractile function, descriptively known as the stunned myocardium.1 Although the myocardium eventually recovers from these transient ischemic episodes, the underlying mechanism(s) responsible for and mediators involved in the reversible dysfunction remain unknown.
Disturbances in the balance of prostacyclin and thromboxane A2 (TxA2) formation have been associ-ated with many disease states, including sudden cardiac death, atherosclerosis, arterial thrombosis, hyperlipidemia, reperfusion arrhythmias, spontaneous and effort induced angina, and other forms of ischemic heart disease. [2] [3] [4] In addition, it has bDeen suggested that the formation of platelet containing thrombi and the release of platelet derived vasoactive mediators such as TxA2 mediate the progression of ischemia induced myocardial damage.5-7These observations have led to speculation that antithrombotic therapy with cyclooxygenase inhibitors such as aspirin may prove to be useful in treating or preventing certain types of cardiovascular disease. Varied results with cyclooxygenase inhibitors in experimental and clinical studies may be attributed to nonselective inhibition of cardioprotective prostanoids also derived from cyclooxygenase. With the recent development of several new compounds which have the specific effect of inhibiting thromboxane synthetase or blocking thromboxane receptors, an alternative approach may be investigated. Experimental studies indicate that these agents may be beneficial in reperfusion induced ventricular arrhythmias2,8 and in irreversible ischemia induced myocardial injury, as determined by creatine kinase release, amino nitrogen loss,5,6,9 and infarct size.7 TxA2, the main arachidonate metabolite from platelets, is a potent vasoconstrictor, platelet aggregator, and membrane destabilizer.10 It has been associated with the progression of ischemic damage following permanent coronary artery occlusion. However, recent evidence suggests that inhibition of thromboxane synthetase reduces infarct size via a redirection of endoperoxides to cardioprotective prostaglandins (PG) rather than by inhibition of TxA2 per se.11 That TxA2 may not be involved in myocardial stunning in reversibly injured myocardium has also been suggested.12 It was concluded that TxA2 did not appear to mediate the prolonged dysfunction or abnormalities in metabolism observed following a brief occlusion and subsequent reperfusion. The purpose of the present study was to investigate further the role of prostaglandin redirection by selective thromboxane synthesis inhibition in the recovery of postischemic regional contractile function in the stunned myocardium by 1) investigating the effects of cyclooxygenase inhibition with indomethacin, 2) assessing cardioprotective effects of TxA2 synthesis inhibition (by dazmegrel) and TxA2 receptor blockade (by BM 13.505), and 3) examining the effects of dazmegrel in the presence of indomethacin. If the beneficial effects of TxA2 synthesis inhibition on functional recovery are due to endoperoxide shunting, indomethacin would be expected to attenuate such dazmegrel mediated effects.
Methods

General Preparation
Adult mongrel dogs of either sex, weighing 19-29 kg, were fasted overnight and anesthetized with sodium barbital (300 mg/kg i.v.) and sodium pentobarbital (15 mg/kg i.v.). The dogs were ventilated at 10-15 breaths/min with a tidal volume of 15 ml/kg (Harvard Respirator) supplemented with 100% 02. A water trap was used to maintain end-expiratory pressure and to prevent atelectasis. Body temperature was maintained at 380 C with a heating pad.
Blood gas samples from the right femoral artery were monitored (Radiometer ABL2) at various times throughout the experiment and maintained within normal physiologic range.
A double-tipped pressure transducer catheter (Millar PC 771) was inserted into the aorta and left ventricle via the carotid artery for the measurements of aortic and left ventricular systolic and diastolic pressures. The left ventricular pressure pulse was electronically differentiated to obtain left ventricular dP/dt as an index of global cardiac contractility. A catheter was inserted into the right femoral vein for the administration of drugs, vehicle, or subsequent anesthesia as needed.
A left thoracotomy was performed at the fifth intercostal space to expose the heart, the lungs were retracted, the pericardium was incised, and the heart was suspended in a cradle. A 1.0 to 1.5 cm segment of the left anterior descending (LAD) coronary artery was dissected free from surrounding tissue just distal to the first diagonal branch. A calibrated electromagnetic flow probe (Statham SP 7515) was placed around the vessel, and LAD coronary blood flow was measured with a flowmeter (Statham 2202). A micrometer driven mechanical occluder was placed on the vessel distal to the flow probe such that there were no branches between the occluder and flow probe. The occluder was used to zero the flow probe as well as to occlude the artery. Heart rate was monitored from limb lead II of the electrocardiogram and a tachograph (Grass Model 7P4F). All hemodynamic variables were monitored on a Grass Model 7 polygraph.
Myocardial Segment Shortening
Regional subendocardial contractile function (% segment shorting, % SS) was measured with two sets of piezoelectric crystals (5 MHz) inserted into the subendocardium (approximately 10-15 mm apart) in the areas perfused by the LAD and the left circumflex coronary arteries. Use of the crystals for this purpose has been described previously.13 Briefly, the crystals were inserted parallel to subendocardial fiber orientation at approximately the same level of the heart in both LAD-and left circumflex-perfused regions. Changes in transmission time of the crystal transmitted sound pulse indicated the distance between the two crystals. Diastolic segment length (DL) was determined at the beginning of the rise phase of positive dP/dt (onset of isovolumic contraction), and systolic segment length (SL) was determined at peak negative dP/dt. The % SS was calculated with the equation % SS=(DL-SL)/DLx100. The segment length data were normalized by using a value of 10.0 for the control DL.14 Regional Myocardial Blood Flow Transmural myocardial tissue blood flow was determined by the radioactive microsphere technique, as described previously.13 Briefly, the left atrial appendage was cannulated for the administration of radioactive microspheres, and the right femoral artery was cannulated for the withdrawal of a reference blood flow sample. Carbonized plastic radioactive microspheres (15+3 ,um diameter) labeled with 14Ce, 51Cr, 103Ru, or 95Nb were suspended in isotonic saline with 0.01% Tween 80, ultrasonicated for 5 minutes, and vortexed for 5 minutes. Microspheres were injected into the left atrium followed by a 6 ml saline flush. Collection of reference blood flow from the right femoral artery, started just prior to sphere administration, was begun at the rate of 6.8 ml/min and continued to a 15 ml collection. Approximately 2 to 4 x 106 microspheres were injected.
At the completion of each experiment, India ink was injected into the LAD immediately distal to the site of occlusion to delineate the hypoperfusion or in vivo risk area while saline was simultaneously injected into the remaining coronary vasculature via the left atrial appendage at equal physiologic pressure (100 mm Hg) to prevent flow through collateral vessels. 12 The heart was then removed, stored overnight in 10% formalin, and subsequently sectioned into subepicardium, midmyocardium, and subendocardium of the normal (three pieces) and ischemic regions (five pieces). To avoid overlap of regional flow, ischemic samples were obtained from at least 1 cm within the ink-stained area. The tissue samples were weighed (approximately 1 g pieces), and all samples were counted in a gamma counter (Searle Analytic 1195) to determine the activity of each isotope in each tissue and reference blood flow sample. Myocardial blood flow was calculated using a programmed computer to obtained the true activity of each isotope in individual samples. Tissue blood flow was determined using the equation: Qm= QrCm/Cr, where Qm is myocardial blood flow (ml/min/g tissue), Qr the rate of withdrawal of the reference blood flow sample (ml/min), C, the activity of the reference blood flow sample (cpm), and Cm the activity of the tissue sample (cpm/g). Transmural tissue blood flow was calculated as the weighted average of the three layers in each region. The ischemic area transmural flow normalized to the nonischemic area in each heart was also calculated.
Prostanoid Measurements
Blood samples obtained at various times from a local coronary vein draining the ischemic-reperfused area were collected into ice-chilled plastic tubes containing 0.8 ml of 0.1 mg/ml indomethacin to prevent ex vivo generation of prostanoids and 0.2 ml of 2.8 mg/ml EDTA as anticoagulant. Blood samples (4 ml) were centrifuged for 10 minutes at 2,500 rpm, and the resulting plasma was stored at -70°C for later analyses. TxB2 and 6-keto PGFia, the stable breakdown products of TxA2 and prostacyclin, respectively, were measured by specific radioimmunoassay (New England Nuclear) as used previously.12,14 Separation of the antibody-antigen complexes from free antigen was achieved by precipitation of the antibody-bound tracer with polyethylene glycol in the presence of carrier immunoglobulin. The amount of radioactivity in the antibody-antigen complex pellet was counted in a gamma counter. The TxB2 antibody showed 3.9% and 0.23% cross-reactivity with PGD2 and PGE2, respectively, and less than 0.07% cross-reactivity with other prostaglandins. The 6-keto-PGF,a antibody showed 2.6% cross-reactivity with PGF2, and less than 2% cross-reactivity with other prostaglandins.
To document the validity of the data obtained from unextracted plasma samples with regard to changes in 6-keto-PGF,a, four additional experiments were performed. In one dog eight sequential samples of blood were obtained from the great cardiac vein and centrifuged at 2,500 rpm for 10 minutes. The plasma was divided into equal volumes: One half was analyzed by radioimmunoassay for 6-keto-PGFl, after extraction of the plasma by the method of Powell, 15 and the other half was analyzed for 6-keto-PGFla from unextracted plasma. A value of 850±240 pg/ml was obtained from the extracted plasma samples and 861±30 pg/ml from the unextracted samples. In an additional three dogs coronary venous blood samples (20 ml) were obtained, and the plasma from each dog was pooled individually. Subsequently, the pooled samples from each dog were divided into 10 control samples and 10 samples in which the plasma was spiked with known quantities of 6-keto-PGFi,a (Sigma Chemical Company) to yield a range of concentrations from 100 to 2,000 pg/ml. It was found that there was significant (p<0.01) linear correlation (r=0.82) between the known amount of 6-ketoPGF1a1 added to the plasma and the amount measured by the specific radioimmunoassay. Thus, on the basis of these additional experiments, we feel confident that changes in 6-keto-PGF,, primarily reflected changes in PGI2 and not some unknown immunoreactive material.
Experimental Protocol
After surgical preparation and stabilization, a pretreatment control (PTC) measurement of hemodynamics, myocardial segment function, blood flow, blood gases, and prostanoids was obtained. Radioactive microspheres were administered before saline or drug intervention. Dogs were randomly divided into one of several of the following groups: saline, control series; dazmegrel 3 mg/kg (DAZ); indomethacin 5 mg/kg (INDO); or BM 13.505 0.5 or 10 mg/kg (BM-0.5 or BM-10), respectively. Saline and all drugs were administered as a slow intravenous bolus given over 2 minutes in 30 ml of saline via the right femoral vein 15 minutes prior to LAD occlusion. In an additional group of animals, DAZ was administered 15 minutes prior to LAD occlusion and 15 minutes following INDO pretreatment. Doses of BM 13.505 were selected which have previously been shown in this laboratory to inhibit markedly the increase in arterial pressure produced by the endoperoxide analog, U46619.12 For the group given dazmegrel alone, the data were taken from a previous study,12 with the addition of one extra dog for completeness and purposes of comparison. Similarly, in the BM-10 group the data were taken from five dogs used in a previous study12 plus six new dogs. There were no differences between the two BM-10 groups so the data were combined into one BM-10 group (n= 11).
In all groups, 10 minutes after drug treatment, hemodynamics, myocardial segment function, and prostanoid measurements were determined. The LAD was occluded for 15 minutes, during which time hemodynamics, myocardial segment shortening, and myocardial blood flow were determined and blood samples obtained. At the end of the ischemic period, the occlusion was initially released, allowing only LAD coronary blood flow (CBF) to return to PTC values, that is, attenuating the reactive hyperemic response. 16 The stenosis was slowly released while keeping LAD coronary blood flow constant. Approximately 15-30 minutes after reperfusion, the occluder was removed from around the LAD. Hemodynamics (Figure 1 ).
Area at Risk
The left ventricular (LV) and area-at-risk weights were similar in all groups ( Table 2 ). The percent of LV at risk (% hypoperfusion area) was also sirnilabetween groups, indicating that equivalent perfusion bed areas were subjected to ischemia.
Regional Myocardial Blood Flow
Tissue Regional myocardial blood flow in the ischemicreperfused area is shown in Table 3 . In all groups significant reductions in regional myocardial blood flow occurred with the greatest deficits in the subendocardium. There were no significant differences in blood flow to any myocardial layer between groups prior to or during occlusion, thus demonstrating that all groups were subjected to comparable degrees of ischemia. At 30 and 180 minutes following reperfusion, no differences were present in regional myocardial blood flow between control and drug-treated groups with the exception of the flow to the subepicardium, which was significantly lower in the INDO and DAZ+INDO groups. In addition, the ratio of transmural blood flow to the ischemic area to transmural blood flow to the nonischemic region (an index of the oxygen supply/demand ratio in the ischemic region) was also similar between groups prior to, during, and following the ischemic period ( Figure 3 . In the control group 6-keto-PGFl, did not change throughout the experiment. However, in the DAZ group there was a significant increase in 6-keto-PGF,,a from occlusion throughout reperfusion (PTC 360±78 pg/ml; peak 6-keto-PGFi, increase to 268±54% of PTC). INDO treatment decreased 6-keto-PGFl, levels, as expected, during occlusion and throughout reperfusion (PTC 362±50 pg/ml; peak 6-keto-PGFl, decrease to 10±3% of PTC). In animals treated with DAZ+INDO, 6-keto-PGFi, levels were significantly decreased throughout the experiment although they were not as depressed as with indomethacin treatment alone (PTC 323±58 pg/ml; peak 6-keto-PGF1I, decrease to 30±10% of PTC).
BM-10 had no effect on 6-keto-PGFl, levels during occlusion or throughout reperfusion.
Myocardial Segment Function
Regional segment shorting in the normal (nonischemic) area remained relatively stable throughout (Figures 4 and  5) . The results shown in Figure 4 illustrate that while functional recovery in the control group was minimal throughout reperfusion (3-hour % SS of PTC, 12±11), % SS in the DAZ group recovered markedly and to a significantly greater extent than % SS in the control group at all times after reperfusion (3-hour % SS of PTC, 66±8). Postischemic group was greater than that of the BM 13.505 -treated dogs.
Discussion
The discoveries of TxA2 and prostacyclin as potent endogenous vasoactive agents have led to the development of new therapeutic approaches for a variety of disease states. While previous reports have shown an involvement by TxA2 in pathologic situations, such as circulatory shock,18 thrombosis,19 reperfusion arrhythmias,2 and the progression of myocardial ischemic damage,7'20 the present results demonstrate conclusively that TxA2 is not an endogenous mediator of the prolonged postischemic dysfunction which occurs following a brief coronary occlusion (myocardial stunning). However, shunting to cardioprotective prostaglandins such as prostacyclin by thromboxane synthetase inhibition appears to result in an improvement in postischemic dysfunction.
Three different methods of inhibiting the formation or action of TxA2 were used in the present study; cyclooxygenase inhibition with indomethacin, TxA2 synthetase inhibition with dazmegrel, and TxA2 receptor blockade with BM 13.505. These different strategies yielded varied effects on functional recovery (see Figure 6 for summary of results and hypothetic mechanisms). The inhibition of arachidonic acid metabolism through the cyclooxygenase pathway by the nonsteroidal antiinflammatory agent, indomethacin, provided no beneficial effect on functional recovery during reperfusion. Similarly, the TxA2 receptor antagonist, BM 13.505, given prior to occlusion, provided no beneficial effects on regional. postischemic contractile function. These data would suggest 
If
Ik cardioprotective actions on functional recovery. Therefore, postischemic functional recovery in the stunned myocardium appears to be associated with the increase in coronary venous 6-keto-PGFl,a during reperfusion, and it does not seem to be related to levels of TxB2. Also, similar to the findings of Mullane and Fornabaio"l in infarct size studies, we have demonstrated that the protective effects of TxA2 synthesis inhibition in the stunned myocardium are prostaglandin mediated. Attenuation of postischemic dysfunction by dazmegrel occurred without any change in myocardial blood flow to the ischemic region or redistribution of flow to subendocardial layers. Enhanced functional recovery also occurred in the absence of changes in myocardial oxygen demand and without a reduction in the loss of systolic wall function observed during the ischemic period. Since treatment with BM 13.505 did not affect hemodynamics or regional myocardial blood flow and since both of these variables were similar to those of the control and dazmegrel-treated groups, differences in functional recovery were not the result of changes in myocardial oxygen supply or demand.
Indomethacin
Indomethacin, a potent cyclooxygenase inhibitor, was utilized in the present study to decrease TxA2 levels and, thus, the actions of TxA2 on both vascular and platelet receptors. Indomethacin did not affect the recovery of function in the stunned myocardium, but this result may not be surprising since prostacyclin was also significantly decreased. Indomethacin exhibited no major effects on hemodynamics prior to or during coronary occlusion. However, throughout reperfusion there was a gradual increase in mean arterial and left ventricular systolic pressures. This increase in afterload produced by indomethacin may have blocked any slight beneficial action indomethacin may have demonstrated in stunned myocardium. In patients with ischemic heart disease, indomethacin has been shown to produce an increase in coronary vascular resistance, as indicated by direct measurements of coronary flow and by increased oxygen extraction.21 This action of indomethacin, however, may be independent of its inhibitory effects on prostaglandin biosynthesis since three other inhibitors of cyclooxygenase, ibuprofen, naproxen, and aspirin, did not cause similar changes in coronary resistance or oxygen extraction.2' At present there is much uncertainty about the effects on nonsteroidal anti-inflammatory agents in ischemic heart disease. In rats treatment with one of three nonsteroidal anti-inflammatory agents decreased the release of lactate dehydrogenase and reduced the release of phosphocreatine on reperfusion in isolated globally ischemic hearts. Although these decreases were significantly correlated with prostaglandin inhibition, indomethacin did not enhance postischemic recovery of mechanical function. SQ 29, 548 , enhanced the recovery of regional segment shortening in stunned myocardium of dogs subjected to 15 minutes of coronary artery occlusion followed by 5 hours of reperfusion. The reasons for the discrepancy between this study and that of Grover and Fulmor27 are not readily apparent but may be related to differences in the experimental model (stenosis vs. no stenosis) or, more likely, to differences in the properties of the receptor antagonist studied. Obviously, more work is needed to resolve this important question. Endoperoxide Steal (Dazmegrel in Presence of Indomethacin)
Previous studies investigating the pathophysiologic role of TxA2 in myocardial ischemic and postischemic injury have concentrated on irreversible tissue damage. Our laboratory has previously suggested that TxA2 may not be involved as a mediator of functional and metabolic stunning.12 The present study strengthens this hypothesis and confirms that in the stunned myocardium the beneficial action of a TxA2 synthesis inhibitor is via a prostaglandin-dependent mecha-nism. The dazmegrel-induced redirection of arachidonic acid metabolism observed in our study is well supported by evidence from other laboratories. 7, 11, 28, 29 Our results are in agreement with those of Mullane and Fornabaio,11 who suggested that in the presence of TxA2 synthetase inhibitors, platelets may be beneficial to the irreversibly injured ischemic myocardium. The platelets are able to donate the prostaglandin endoperoxide, PGH2, which may be converted in the blood or plasma to potentially beneficial prostanoids such as PGD2, PGE2, or prostacyclin and in the vessel wall to prostacyclin. 1 In human volunteers 120 minutes after injection of CV-4151, a thromboxane synthetase inhibitor, serum TxB2 was reduced by 85-96% whereas there was a four to sixfold increase in 6-keto-PGFia. 29 This process has been termed endoperoxide steal.
While the prostacyclin mimetic, iloprost, given prior to or during occlusion has been shown to enhance postischemic functional recovery significantly in the stunned myocardium,30 no studies have been performed with prostacyclin, PGE2, or PGD2. However, all three prostanoids are able to vasodilate, antiaggregate platelets, and inhibit the superoxide burst from neutrophils.11 Also, catecholamine loss, which has been shown to occur during occlusion and/or early reperfusion, may be prevented by prostacyclin. In addition, Aiken and coworkers28 have demonstrated that the antiaggregatory and antithrombotic efficacy of TxA2 synthesis inhibition is due in part to the enhancement of endogenous prostacyclin release.
Although the reason or reasons for the dazmegrel induced functional enhancement during reperfusion are not obvious, there are several mechanisms involving endoperoxide shunting which may be in effect. Myocardial stunning has been suggested to be due in part to a decreased coupling of myofibrillar creatine kinase and ATPase.31 Thus, a dazmegrel related increase in adenine nucleotide levels12 may increase free ADP concentrations for creatine kinase or the amount of ATP for myosin ATPase. Pissarek et a132 have observed a preservation of myocardial high energy phosphates in dogs pretreated with prostacyclin or iloprost following 3 hours of coronary occlusion. Postischemic dysfunction in the stunned myocardium has also been related to the presence of oxygen-derived free radicals.33-36 Some potential sources of free radical formation include arachidonic acid metabolism, catecholamine auto-oxidation, mitochondrial electron transport disruption, xanthine oxidase, and activated neutrophils.37 Possible inhibition of catecholamine release would decrease free radical production, as might membrane stabilization by prostacyclin. Neutrophils and neutrophil derived mediators, postulated to play an important role in mediating the progression of long-term ischemic damage,38 have also been suggested to be a major cause of myocardial stunning in one study39 but not another. 4 The neutrophil oxidative burst has previously been shown to be inhibited in the presence of prostacyclin,4 iloprost,30 PGE2, and PGD2.1l Endoperoxide shunting to prostacyclin, PGE2, and PGD2 may inhibit neutrophil superoxide release and in this way enhance postischemic recovery.
Conclusion
Unlike certain models of ischemic injury, TxA2, is not involved in reversible postischemic dysfunction, and inhibition of TxA2 significantly attenuates postischemic dysfunction in the stunned myocardium only in the presence of enhanced prostacyclin production. Inhibiting the formation of TxA2 with indomethacin or antagonizing the action of TxA2 at its receptors has no beneficial effect on functional recovery, and blocking the dazmegrel induced endoperoxide shunting also abolishes the cardioprotective effect of dazmegrel ( Figure 6 ). TxA2 synthesis inhibition may still be of therapeutic benefit in transient ischemic events via shunting to cardioprotective prostanoids.
